FDA approves Monjuvi for relapsed, refractory follicular lymphoma
The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Jun 23, 2025
0
14
Amino Acids, Peptides, and Proteins: News and Research on Antibodies, Monoclonal, Murine-Derived
MeSH tree: D12.776.377.715.548.114.224.284
Simple algorithm helps improve treatment, reduce racial disparities for patients with multiple sclerosis
A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will be presented at the ...
Mar 3, 2025
0
11
Clinical trial: Off-the-shelf immunotherapy shows promise for B-cell lymphoma
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could make future cellular immunotherapies less expensive and more accessible to patients.
Jan 14, 2025
0
33
Treatment method does not improve survival for mantle cell lymphoma patients, clinical trial shows
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment. ...
Dec 10, 2024
0
21
Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone lymphoma.
Dec 9, 2024
0
47
Anti-CD20 therapy shows no effect on disability progression in MS
For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and untreated, according to a study published online ...
Sep 26, 2024
0
47
Study finds certain multiple sclerosis therapies may not slow disability progression
In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not receiving treatment. ...
Sep 25, 2024
0
40
Early treatment significantly reduces long-term disability in children with multiple sclerosis, new study finds
New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, ...
Sep 17, 2024
0
49
Light-activated macrophages show increased appetite for cancer cells
The body has a veritable army constantly on guard to keep us safe from microscopic threats from infections to cancer. Chief among these forces is the macrophage, a white blood cell that surveils tissues and consumes pathogens, ...
Aug 12, 2024
0
54
Understanding the immune system's 'big eater': New insights into macrophage behavior in cancer therapy
Do you want the bad news, good news or better news? The bad news is that cancer continues to be the second leading cause of death in the United States, trailing heart disease. The good news is that overall cancer mortality ...
Jun 7, 2024
0
54
